cryptocurrency sales- Top searches

NVIDIA Tmall flagship store emptied all the goods off the shelves? Insider: Tmall flagship store has always been used only for displaying goods, and it is not directly sold, so there is no such thing as "off the shelf". On December 12th, the media wrote that all the goods in NVIDIA Tmall flagship store were emptied off the shelf. Interface news learned from insiders that the flagship store is only used for displaying goods, and it is not directly sold, so there is no such thing as "off the shelf". The reporter browsed the Tmall platform "NVIDIA GeForce Flagship Store" and found that the "Baby" column was empty. Informed sources told that this interface was always empty, and consumers could browse the product information through the "Classification" interface column and be guided to the flagship stores of ASUS, Gigabyte and other manufacturers through links to place orders. (Interface News)CITIC Securities: The resonance between supply and demand of medical beauty accelerates the space expansion, and the difference in operating ability promotes the evolution of the industry structure. CITIC Securities Research Report stated that the medical beauty industry has both medical and consumption attributes, and the medical attribute has strong product-driven characteristics, while the consumption attribute has high operating ability requirements. The medical beauty botulinum toxin track is also affected by the dual attributes of medicine and consumption: 1) The increase in penetration rate, the acceleration of compliance substitution and the extension of indications have brought about high demand for medical beauty botulinum toxin, and with the recent supply expansion, the industry scale has experienced high growth; 2) The iteration of product innovation is slow, brand barriers are created through marketing, doctors are empowered through direct sales, and control is strengthened to enhance product competitiveness. Recently, a variety of medical botulinum toxins in China have been approved, and the promotion of low-priced products is expected to push up the penetration rate, and enterprises with strong operational capabilities will enter the market or promote the evolution of the pattern.Lu 'an Huaneng: The raw coal output in November was 5.09 million tons, down 5.39% year-on-year. Lu 'an Huaneng announced that the raw coal output in November 2024 was 5.09 million tons, down 5.39% year-on-year; The sales volume of commercial coal was 5.36 million tons, up 18.32% year-on-year. In 2024, the cumulative output of raw coal was 52.25 million tons, down 4.88% year-on-year; The cumulative sales volume of commercial coal was 47.09 million tons, down 4.48% year-on-year.

Yuncong Technology: "The R&D team of large-scale model agent products is basically dissolved" is all false information. Yuncong Technology said on the interactive platform that the company's R&D team is stable at present, and a rigorous and meticulous hierarchical division of labor system has been established for the research and development of large-scale model related products. The configuration of R&D echelon will be flexibly adjusted according to the continuous evolution of large model technology and the changes of market demand of agent products. The statements of "the No.1 position of the big model algorithm" and "the R&D team of the big model agent product is basically dissolved" mentioned in the question are false information, and the company reserves the right to pursue legal responsibility for this. The company has been unswervingly promoting the research and product development of large-scale model and agent-related technologies.Tongfu Microelectronics traded 2.24 million shares at a discount of 60.0768 million yuan today. Tongfu Microelectronics traded 2.24 million shares at a discount of 60.0768 million yuan today, accounting for 3.32% of the total turnover of the day, and the transaction price was 26.82 yuan, which was 9.97% lower than the market closing price of 29.79 yuan.Laimei Pharmaceutical Co., Ltd.: The controlling shareholder intends to transfer 23.43% of the shares by agreement. Laimei Pharmaceutical announced that Zhongheng Group, the controlling shareholder, intends to transfer 247 million shares of the company's unrestricted tradable A shares by public solicitation of the transferee, accounting for 23.43% of the company's total share capital, and the transfer price is not less than 4.42 yuan/share. If the share transfer is completed, the controlling shareholder and actual controller of the company may change.

Yin Zhongyu, Federal Reserve Securities: Industrial M&A will always have the opportunity to cross-border M&A and will never be supported on a large scale. Yin Zhongyu, assistant to the president of Federal Reserve Securities and head of the M&A business department, pointed out that M&A has ushered in a rare policy window. For industrial M&A, the policy window has always been there. "In particular, industrial M&A focusing on new productivity has always been the direction encouraged by the regulatory authorities, and there will always be opportunities. However, for buying and selling shells and cross-border restructuring, related risks need to be vigilant, and cross- (21 Finance)Jianfan Bio: The plasma separator was certified by the European Union MDR, and Jianfan Bio announced that Jianfan Blood Purification Company, a wholly-owned subsidiary, recently received a notice from the EU announcement agency that its plasma separator was certified by the European Union MDR in accordance with the EU Medical Devices Regulation 2017/745, and can be sold in EU countries and other countries that recognize the EU CE certification.French President Macron: Without Europeans, Europe will not be safe.